Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.

The apparent reduction in deaths attributed to other medical causes in participants originally allocated simvastatin (200 [2·3%] vs 239 [2·8%]) was only marginally significant (p=0·03) and involved no material differences in deaths due to renal or hepatic disease and only a non-significant difference in a miscellaneous group of other non-vascular causes.

also in 5,085 other papers